Top

Published in:

01-03-2007

Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions

Authors: Michael A. Burke, William G. Cotts

Published in: Heart Failure Reviews | Issue 1/2007

Abstract

B-Type natriuretic peptide (BNP) is elevated in states of increased ventricular wall stress. BNP is most commonly used to rule out congestive heart failure (CHF) in dyspneic patients. BNP levels are influenced by age, gender and, to a surprisingly large extent, by body mass index (BMI). In addition, it can be elevated in a wide variety of clinical settings with or without CHF. BNP is elevated in other cardiac disease states such as the acute coronary syndromes, diastolic dysfunction, atrial fibrillation (AF), amyloidosis, restrictive cardiomyopathy (RCM), and valvular heart disease. BNP is elevated in non-cardiac diseases such as pulmonary hypertension, chronic obstructive pulmonary disease, pulmonary embolism, and renal failure. BNP is also elevated in the setting of critical illness such as in acute decompensated CHF (ADHF) and sepsis. This variation across clinical settings has significant implications given the increasing frequency with which BNP testing is being performed. It is important for clinicians to understand how to appropriately interpret BNP in light of the comorbidities of individual patients to maximize its clinical utility. We will review the molecular biology and physiology of natriuretic peptides as well as the relevant literature on the utilization of BNP in CHF as well as in other important clinical situations, conditions that are commonly associated with CHF and or dyspnea.

Lok C, Morgan C, Ranganathan N (1998) The accuracy and interobserver agreement in detecting the ‘gallop sounds’ by cardiac auscultation. Chest 114:1283–1288PubMed

Butman S, Ewy G, Standen J, Kern K, Hahn E (1993) Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distention. J Am Coll Cardiol 22:968–974PubMedCrossRef

Fonseca C, Morais H, Mota T et al (2004) The diagnosis of heart failure in primary care: value of signs and symptoms. Eur J Heart Fail 6:795–800PubMed

Dao Q, Krishnaswamy P, Kazanegra R et al (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37:379–385PubMed

Maisel A, Krishnaswamy P, Nowak R et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167PubMed

Januzzi J, Camargo C, Anwaruddin S et al (2005) The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 95:948–954PubMed

Silver M, Maisel A, Yancy C et al (2004) BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10:1–30

Cowie M, Mendez G (2002) BNP and congestive heart failure. Prog Cardiovasc Dis 44:293–321PubMed

de Denus S, Pharand C, Williamson D (2004) Brain natriuretic peptide levels in the management of heart failure: the versatile neurohormone. Chest 125:652–668PubMed

10.

Rodeheffer R (2004) Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 44:740–749PubMed

11.

Giuliani I, Rieunier F, Larue C et al (2006) Assay for measurement of intact B-Type natriuretic peptide prohormone in blood. Clin Chem 6:1054–1061

12.

Luchner A, Stevens T, Borgeson D et al (1998) Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274:H1684–H1689PubMed

13.

Luchner A, Muders F, Dietl O et al (2001) Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res 51:601–607PubMed

14.

Yasue H, Yoshimura M, Sumida H et al (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMed

15.

Adams K, Mathur V, Gheorghiade M (2003) B-type natriuretic peptide: From bench to bedside. Am Heart J 145:S34–S46PubMed

16.

Liang F, Wu J, Garami M, Gardner D (1997) Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem 272:28050–28056PubMed

17.

Liang F, Gardner D (1998) Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J Biol Chem 273:14612–14619PubMed

18.

Liang F, Gardner D (1999) Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 104:1603–1612PubMedCrossRef

19.

Iwanaga Y, Nishi I, Furuichi S et al (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47:742–748PubMed

20.

Wiese S, Breyer T, Dragu A et al (2000) Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102:3074–3079PubMed

21.

He Q, Wu G, LaPointe M (2000) Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac. Am J Physiol Endocrinol Metab 278:E1115–E1123PubMed

22.

Houben A, van der Zander K, de Leeuw P (2005) Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 19:411–419PubMed

23.

McGrath MF, Kuroski de Bold ML, de Bold AJ (2005) The endocrine function of the heart. Trends Endocrinol Metab 16:469–477PubMed

24.

Wu A, Smith A, Wieczorek S et al (2003) Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628–631PubMed

25.

Bruins S, Fokkema M, Römer J et al (2004) High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50:2052–2058PubMed

26.

Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982PubMed

27.

Maisel AS, Clopton P, Krishnaswamy P et al (2004) Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147:1078–1084PubMed

28.

Mueller C, Laule-Kilian K, Frana B et al (2005) The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnea. J Intern Med 258:77–85PubMed

29.

Berdagué P, Caffin P, Barazer I et al (2006) Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J 151:690–698PubMed

30.

McCord J, Mundy B, Hudson M et al (2004) Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164:2247–2252PubMed

31.

Daniels LB, Clopton P, Bhalla V et al (2006) How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: Results from the Breathing Not Properly Multinational Study. Am Heart J 151:999–1005PubMed

32.

Krauser D, Lloyd-Jones D, Chae C et al (2005) Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149:744–750PubMed

33.

Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108:13–16PubMed

34.

Nakayama T (2005) The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J 52:11–21PubMed

35.

Troughton R, Prior D, Pereira J et al (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43:416–422PubMed

36.

Yap L (2004) B-type natriuretic peptides and the right heart. Heart Fail Rev 9:99–105PubMed

37.

Pedersen E, Bacevicius E, Bech J, Solling K, Pedersen H (2006) Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in chronic renal failure. Clin Sci 110:491–501PubMed

38.

Knudsen CW, Clopton P, Westheim A et al (2005) Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the Breathing Not Properly Multinational Study. Ann Emerg Med 45:573–580PubMed

39.

Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2005) Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91:606–612PubMed

40.

Doust J, Glasziou P, Pietrzak E, Dobson A (2004) A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164:1978–1984PubMed

41.

Latour-Pérez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J (2006) Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail 4:390–399

42.

Maisel A, Hollander J, Guss D et al (2004) Primary results of the rapid emergency department heart failure outpatient trial (REDHOT). J Am Coll Cardiol 2004:1328–1333

43.

Brenden CK, Hollander JE, Guss D et al (2006) Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am Heart J 151:1013–1018

44.

Mueller C, Scholer A, Laule-Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654PubMed

45.

Doust J, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 330:625

46.

Vrtovec B, Delgado R, Zewail A, Thomas C, Richartz B, Radovancevic B (2003) Prolonged QTc and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 107:1764–1769PubMed

47.

Latini R, Masson S, Anand I et al (2004) The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25:292–299PubMed

48.

Maeda K, Tsutamoto T, Wada A et al (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587–1593PubMed

49.

Stanek B, Frey B, Hülsmann M et al (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blockade therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38:436–442PubMed

50.

Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Schmidt W (2001) Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38:1934–1941PubMed

51.

Harrison A, Morrison L, Krishnaswamy P et al (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39:131–138PubMed

52.

Richards A, Doughty R, Nicholls M et al (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37:1781–1787PubMed

53.

Gardner R, Özalp F, Murday A, Robb S, McDonagh T (2003) N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735–1743PubMed

54.

Logeart D, Thabut G, Jourdain P et al (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk for re-admission after decompensated heart failure. J Am Coll Cardiol 43:635–641PubMed

55.

Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A (2004) N-terminal-pro-brain natriuretic peptide predicts outcomes after hospital discharge in heart failure patients. Circulation 110:2168–2174PubMed

56.

Verdiani V, Nozzoli C, Bacci F et al (2005) Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 7:566–571PubMed

57.

Hartmann F, Packer M, Coats A et al (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvediolol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110:1780–1786PubMed

58.

Anand I, Fisher L, Chiang Y et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMed

59.

Wang T, Larson M, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663PubMed

60.

Vasan R, Benjamin E, Larson M et al (2002) Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 288:1252–1259PubMed

61.

Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J (2004) Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community based study. Circulation 109:3176–3181PubMed

62.

Nakamura M, Tanaka F, Sato K et al (2005) B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail 11:705–712PubMed

63.

Redfield MM, Jacobsen SJ, Burnett JC et al (2003) Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 289:194–202PubMed

64.

Vanderheyden M, Goethals M, Verstreken S et al (2004) Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44:2349–2354PubMed

65.

Lubien E, DeMaria A, Krishnaswamy P et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. Circulation 105:595–601PubMed

66.

Brucks S, Little W, Chao T et al (2005) Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 95:603–606PubMed

67.

Arteaga E, Araujo AQ, Buck P et al (2005) Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150:1228–1232PubMed

68.

Conen D, Zeller A, Pfisterer M, Martina B (2006) Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 97:249–252PubMed

69.

Lukowicz T, Fischer M, Hense H et al (2005) BNP as a marked of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail 7:525–531PubMed

70.

Dahlström U (2004) Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 6:281–287PubMed

71.

Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41:2010–2017PubMed

72.

Wiviott S, de Lemos J, Morrow D (2004) Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 346:119–128PubMed

73.

Richards A, Nicholls M, Yandle T et al (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921–1929PubMed

74.

de Lemos J, Morrow D, Bentley J et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014–1021PubMed

75.

Omland T, de Lemos J, Morrow D et al (2002) Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 89:463–465PubMed

76.

Omland T, Persson A, Ng L et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106:2913–2918PubMed

77.

James S, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable angina coronary artery disease: a Global Utilization of Strategies to Open occluded arteries (GUSTO)-IV substudy. Circulation 2003:275–281

78.

Morrow D, de Lemos J, Sabatine M et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41:1264–1272PubMed

79.

Sabatine M, Morrow D, de Lemos J et al (2004) Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44:1988–1995PubMed

80.

Takemura G, Takatsu Y, Doyama K et al (1998) Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 31:254–265

81.

Palladini G, Campana C, Klersy C et al (2003) Serum N-terminal Pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440–2445PubMed

82.

Nordlinger M, Magnani B, Skinner M, Falk R (2005) Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 96:982–984PubMed

83.

Leya F, Arab D, Joyal D et al (2005) The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45:1900–1902PubMed

84.

Babuin L, Alegria JR, Oh JK et al (2006) Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J Am Coll Cardiol 47:1489–1491PubMed

85.

Silvet H, Young-Xu Y, Walleigh D, Ravid S (2003) Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92:1124–1127PubMed

86.

Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6:92–96PubMed

87.

Wozakowska-Kaplon B (2004) Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 93:1555–1558PubMed

88.

Shin DI, Jaekel K, Schley P et al (2005) Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 94:795–800PubMed

89.

Yamada T, Murakami Y, Okada T et al (2006) Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation. Am J Cardiol 97:1741–1744PubMed

90.

Lee SH, Jung JH, Choi SH et al (2006) Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 70:100–104PubMed

91.

Knudsen C, Omland T, Clopton P et al (2005) Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients. J Am Coll Cardiol 46:838–844PubMed

92.

Gerber I, Stewart R, Legget M et al (2003) Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107:1884–1890PubMed

93.

Nessmith M, Fukuta H, Brucks S, Little W (2005) Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96:1445–1448PubMed

94.

Eimer M, Ekery DL, Rigolin VH et al (2004) Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 94:676–678PubMed

95.

Detaint D, Messika-Zeitoun D, Avierinos J et al (2005) B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111:2391–2397PubMed

96.

Arat-Ozkan A, Kaya A, Yigit Z et al (2005) Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 22:473–478PubMed

97.

Yap L, Mukerjee D, Timms P, Ashrafian H, Coghlan J (2004) Natriuretic peptides, respiratory disease, and the right heart. Chest 126:1330–1336PubMed

98.

McCullough PA, Hollander JE, Nowak RM et al (2003) Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 10:198–204PubMed

99.

Morrison LK, Harrison A, Krishnaswamy P et al (2002) Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39:202–209PubMed

100.

Mueller C, Laule-Kilian K, Frana B et al (2006) Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 151:471–477PubMed

101.

Pieralli F, Olivotto I, Vanni S et al (2006) Usefulness of bedside brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 97:1386–1390PubMed

102.

Kruger S, Graf J, Merx MW et al (2004) Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 147:60–65PubMed

103.

Nagaya N, Nishikimi T, Okano Y et al (1998) Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31:202–208PubMed

104.

Leuchte HH, Baumgartner RA, Nounou ME et al (2006) Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Resp Crit Care Med 173:744–750PubMed

105.

Maeder M, Fehr T, Rickli H, Ammann P (2006) Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 129:1349–1366PubMed

106.

Hoffman U, Borggrefe M, Brueckmann M (2006) New horizons: NT-proBNP for risk stratification of patients with shock in the intensive care unit. Crit Care 10:134

107.

Charpentier J, Luyt C, Fulla Y et al (2004) Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 32:660–665PubMed

108.

Tung RH, Garcia C, Morss AM et al (2004) Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 32:1643–1647PubMed

109.

Brueckmann M, Huhle G, Lang S et al (2005) Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112:527–534PubMed

110.

Roch A, Allardet-Servent J, Michelet P et al (2005) NH₂ terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 33:1001–1007PubMed

111.

Januzzi JL, Morss A, Tung R et al (2006) Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 10:R37PubMed

112.

Witthaut R, Busch C, Fraunberger P et al (2003) Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 29:1696–1702PubMed

113.

Jefic D, Lee J, Jefic D, Savoy-Moore R, Rosman H (2005) Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 128:288–295PubMed

114.

Rudiger A, Gasser S, Fischler M et al (2006) Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 34:2140–2144PubMed

115.

Thierry LB, Brocas E, Van de Louw A et al (2006) B-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 50:340–347PubMed

116.

Kazanegra R, Cheng V, Garcia A et al (2001) A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7:21–29PubMed

117.

O’Neill J, Bott-Silverman C, McRae AI, Troughton R, Starling R, Young J (2005) B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149:363–369PubMed

118.

Forfia PR, Watkins SP, Rame JE et al (2005) Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45:1667–1671PubMed

119.

James KB, Troughton RW, Feldschuh J et al (2005) Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. Am Heart J 150:984.e1–984.e6

120.

Shlipak M, Massie B (2004) The clinical challenge of cardiorenal syndrome. Circulation 110:1514–1517PubMed

121.

McCullough P, Duc P, Omland T et al (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly multinational study. Am J Kid Dis 41:571–579PubMed

122.

Mueller C, Laule-Kilian K, Scholer A et al (2005) B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 67:278–284PubMed

123.

Takami Y, Horio T, Iwashima Y et al (2004) Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kid Dis 44:420–428PubMed

124.

Wu A, Omland T, Knudsen C et al (2005) Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) multinational study. Am J Hematol 80:174–180PubMed

125.

Vickery S, Price C, John I et al (2005) B-type natriuretic peptide and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kid Dis 46:610–620PubMed

126.

McCullough P, Sandberg K (2003) B-type natriuretic peptide and renal disease. Heart Fail Rev 8:355–358PubMed

127.

Anwaruddin S, Lloyd-Jones D, Baggish A et al (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. J Am Coll Cardiol 47:91–97PubMed

128.

Tsutamoto T, Wada A, Sakai H et al (2006) Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47:582–586PubMed

129.

Dastoor H, Bernieh B, Boobes Y et al (2005) Plasma BNP in patients on maintenance hemodialysis: a guide to management? J Hypertens 23:23–28PubMed

130.

Genest J, Granger P, de Champlain J, Boucher R (1968) Endocrine factors in congestive heart failure. Am J Cardiol 22:35–42PubMed

131.

Packer M (2003) Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure. Circulation 108:2950–2953PubMed

132.

Maisel A (2006) The coming of age of natriuretic peptides: the emperor does have clothes! J Am Coll Cardiol 47:61–64PubMed

133.

Cohn JN (2006) B-type natriuretic peptide had reduced specificity for diagnosing heart failure and dyspnea with atrial fibrillation in the emergency department. [Comment]. ACP J Club 144:48PubMed

134.

Colucci W, Elkayam U, Horton D et al (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343:246–253PubMed

135.

Burger A, Horton D, LeJemtel T et al (2002) Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 144:1102–1108PubMed

136.

Publication committee for the VMAC investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287:1531–1540

137.

Hawkridge A, Heublein D, Bergen H, Cataliotti A, Burnett J, Muddiman D (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci 102:17442–17447PubMed

138.

Troughton R, Frampton C, Yandle T, Espiner E, Nicholls M, Richards A (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130PubMed

139.

Lee D, Vasan R (2005) Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20:201–210PubMed

Title: Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions
Authors: Michael A. Burke
William G. Cotts
Publication date: 01-03-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Heart Failure Reviews / Issue 1/2007
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-007-9002-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

MR spectroscopy in heart failure—clinical and experimental findings

The use of transcriptomic biomarkers for personalized medicine

Renal dysfunction in heart failure patients: what is the evidence?

Theoretical rationale and practical recommendations for cardiopulmonary exercise testing in patients with chronic heart failure

Cardiac hypertrophy induced by sustained β-adrenoreceptor activation: pathophysiological aspects

The influence of diabetes on cardiac β-adrenoceptor subtypes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page